Abeona Therapeutics

Abeona Therapeutics Inc. (Nasdaq: ABEO) is a leading clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. Abeona's lead programs are ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU), adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome (MPS IIIA and IIIB), respectively. We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, Abeona is developing plasma protein therapies, including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD, using our proprietary SDF™ (Salt Diafiltration) ethanol-free process.

Dallas, US
Size (employees)
6 (est)
Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US

Abeona Therapeutics Office Locations

Abeona Therapeutics has office in Dallas
Dallas, US

Abeona Therapeutics Metrics

Abeona Therapeutics Summary

Market capitalization

$201.8 m

Closing share price

Abeona Therapeutics's current market capitalization is $201.8 m.

Abeona Therapeutics Financials

Abeona Therapeutics's revenue is $2 m in FY, 2013 which is a 120.8% increase from the previous period.
FY, 2013FY, 2014FY, 2015


$2 m$925 k$1 m

Revenue growth, %


Net Income

$4.4 m($26.8 m)($14.5 m)

Abeona Therapeutics Market Value History

Abeona Therapeutics Online Presence

Abeona Therapeutics Company Life

You may also be interested in